½ÅÃ̼¼ºê¶õ½ºº´¿ø [´ëÇѳúÀüÁõÇÐȸ] 2022³âµµ 10¿ù º¸¼ö±³À° : 2022-10-29±³À°ÀÏÀÚ : 2022-10-29
±³À°Àå¼Ò : ½ÅÃ̼¼ºê¶õ½ºº´¿ø Àº¸í´ë°´ç(º»°ü 6Ãþ)
±³À°ÁÖÁ¦ :
[´ëÇѳúÀüÁõÇÐȸ] 2022³âµµ 10¿ù º¸¼ö±³À°ÁÖÃÖ±â°ü : ´ëÇѳúÀüÁõÇÐȸ
´ã´çÀÚ : ±è¼Ò¿¬
¿¬¶ôó : 02-362-9662
À̸ÞÀÏ :
epilepsy@kes.or.kr ±³À°Á¾·ù : ¼Ò¾Æû¼Ò³â°ú, Á¤½Å°Ç°ÀÇÇаú, ½Å°æ¿Ü°ú, ½Å°æ°úÀÇ»çÇÐ, ÀÇ·á»çȸÇÐ, ÀÇ·áÁ¤Ã¥
Âü¼®¿¹»óÀοø : 150¸í
Èñ¸ÁÆòÁ¡ : 5Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 5 ½Ã°£ 10ºÐ
¼¼ºÎ¼ö°·á : 40,000¿ø
ºñ°í [ȸ¿ø]Àü¹®ÀÇ: 32,000¿ø / Àü°øÀÇ: 24,000¿ø[ºñȸ¿ø]Àü¹®ÀÇ: 40,000¿ø / Àü°øÀÇ: 30,000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 10-29 Àº¸í´ë°´ç 13:00~13:10 Àλ縻 Çã°æ(´ëÇѳúÀüÁõÇÐȸ ÀÌ»çÀå)
±³À°½Ã°£ 10-29 Àº¸í´ë°´ç 13:10~13:40 Implications of new classification of seizure and epilepsy ¹Ú°æÀÏ(¼¿ïÀÇ´ë ½Å°æ°ú)
±³À°½Ã°£ 10-29 Àº¸í´ë°´ç 13:40~14:10 Updated in terminology and classification of status epilepticus ÀÌÀ±Áø(ºÎ»êÀÇ´ë ¼Ò¾Æû¼Ò³â°ú)
±³À°½Ã°£ 10-29 Àº¸í´ë°´ç 14:10~14:30 Self-limited epilepsy in childhood ±è¹ÎÁö(¿ï»êÀÇ´ë ¼Ò¾Æû¼Ò³â°ú)
±³À°½Ã°£ 10-29 Àº¸í´ë°´ç 14:30~14:50 Idiopathic generalized epilepsy ±èÇå¹Î(¼¿ïÀÇ´ë ¼Ò¾Æû¼Ò³â°ú)
±³À°½Ã°£ 10-29 Àº¸í´ë°´ç 14:50~15:10 Elderly patients with epilepsy ±è±ÙÅÂ(°è¸íÀÇ´ë ½Å°æ°ú)
±³À°½Ã°£ 10-29 Àº¸í´ë°´ç 15:10~15:30 Women and pregnancy Ȳ°æÁø(°æÈñÀÇ´ë ½Å°æ°ú)
±³À°½Ã°£ 10-29 Àº¸í´ë°´ç 15:30~15:50 Epilepsy with commorbid conditions ¼Á¾±Ù(°æºÏÀÇ´ë ½Å°æ°ú)
ÈÞ½Ä 10-29 Àº¸í´ë°´ç 15:50~16:10 coffee break ()
±³À°½Ã°£ 10-29 Àº¸í´ë°´ç 16:10~16:30 Second-line therapy for status epilepticus ÇѼöÇö(Áß¾ÓÀÇ´ë ½Å°æ°ú)
±³À°½Ã°£ 10-29 Àº¸í´ë°´ç 16:30~16:50 New-on refractory status epilepticus ÀÌ¿ìÁø(¼¿ïÀÇ´ë ½Å°æ°ú)
±³À°½Ã°£ 10-29 Àº¸í´ë°´ç 16:50~17:10 Concept and rescue treatment for acute seziure clusters ±è¿ìÁß(¼¿ïÀÇ´ë ¼Ò¾Æû¼Ò³â°ú)
±³À°½Ã°£ 10-29 Àº¸í´ë°´ç 17:10~17:40 Orphan anti-seizure medications for rare genetic epilepsies ±è¼¼Èñ(¿¬¼¼ÀÇ´ë ¼Ò¾Æû¼Ò³â°ú)
±³À°½Ã°£ 10-29 Àº¸í´ë°´ç 17:40~18:10 Third generation anti-seizure medications ¼±¿ìÁØ»ó(°ºÏ»ï¼ºº´¿ø ½Å°æ°ú)
±³À°½Ã°£ 10-29 Àº¸í´ë°´ç 18:10~18:40 Clinical utility of extended-release anti-seizure medications ÀüÁø¼±(ÇѸ²ÀÇ´ë ½Å°æ°ú)
±âŸ 10-29 Àº¸í´ë°´ç 18:40~18:50 Closing remarks ÀÓº´Âù(´ëÇѳúÀüÁõÇÐȸ ¼ö·Ã±³À°ÀÌ»ç)